Shimadzu partners with Protein Metrics to provide advanced solutions for biotherapeutic protein analysis
Posted: 21 June 2018 | Shimadzu | No comments yet
Shimadzu, one of the world’s fastest growing mass spectrometry companies and Protein Metrics Inc., a leading provider of mass spectrometry software for protein characterisation, today announced a co-marketing agreement for the use of Byos™ with Shimadzu Q-TOF technology…
The co-marketing agreement combines Shimadzu’s latest Q-TOF technology with Protein Metrics’ software, which automates biotherapeutic characterisation workflows.
“The development of biopharmaceutical medicines is challenging and dynamic, and expands the demand for bioanalytical capability. Automating core biologics workflows is a key part of this bioanalytical capability. To advance this process and to provide better tools for protein researchers, we are working with Protein Metrics to help deliver better decisions on biologics workflows using our LCMS-9030 Q-TOF mass spectrometer. We’re proud to work with Protein Metrics and excited about the opportunity this partnership offers our customers,”
said Ichiro Hirano, LCMS Product Manager, Shimadzu Corporation.
“As Shimadzu continues to open new markets for its leading mass spec portfolio, we are proud to partner with them in the biopharma and protein analysis segments,”
says Eric Carlson, Ph.D., President and CEO of Protein Metrics.
“As Protein Metrics continues to add scientific support in APAC, and as we see significant adoption of our products worldwide, we’re very excited to offer our customers the benefits of automatic processing of Shimadzu raw data files.”
Related topics
Analytical techniques, Biopharmaceuticals, Lab Equipment, Liquid Chromatography - Mass Spectrometry (LC-MS), Mass Spectrometry, Proteins, Technology
